The Intellectual Property Nicotine War: How Patents Are Shaping the Future of Reduced-Risk Products

When Philip Morris International acquired Swedish Match for $16 billion in 2023, the acquisition was widely understood as a strategic bet on nicotine pouches—the smoke-free, tobacco-free oral product that Swedish Match's ZYN brand dominates. But the acquisition was also an intellectual property play. Swedish Match's patent portfolio—covering the manufacturing process for nicotine pouches, the pouch material, the nicotine formulation, and the user experience—gave PMI control over the foundational technology of the fastest-growing nicotine category. The acquisition was not just a market-entry strategy. It was a patent-acquisition strategy. The nicotine industry's transformation from combustible cigarettes to reduced-risk products is, at a fundamental level, a technology transition—and technology transitions are fought and won on intellectual property.

The patent landscape for nicotine products has exploded in complexity over the past decade. The US Patent and Trademark Office (USPTO) and its international counterparts have received thousands of patent applications covering every aspect of reduced-risk nicotine products: heating technologies (induction vs. resistive vs. infrared), nicotine formulations (freebase vs. salt vs. synthetic vs. encapsulated), delivery formats (pods vs. disposables vs. pouches vs. inhalers vs. films), device features (temperature control, dose metering, child resistance, connectivity), and manufacturing processes (automated assembly, quality control, track-and-trace). The major tobacco companies have built patent portfolios that, in scope and sophistication, rival those of pharmaceutical and consumer-electronics companies. The patent thicket that has grown around reduced-risk nicotine products serves the strategic interests of the companies that own the patents: it creates barriers to entry for competitors, provides assets that can be licensed or litigated, and shapes the direction of technological development in ways that favor the patent holders.

The public health implications of the nicotine patent landscape are underexamined. Patents are monopoly rights—they grant the patent holder the exclusive right to use, manufacture, and sell the patented technology for a period of 20 years from the filing date. In the pharmaceutical industry, patents on brand-name drugs delay the availability of generic alternatives, keeping drug prices high and limiting access. The same dynamic is emerging in the nicotine industry. The patents that protect the major companies' reduced-risk products also prevent competitors from entering the market with potentially safer, more effective, or more affordable alternatives. The patent system, designed to incentivize innovation, can also function to suppress it—by allowing patent holders to block innovations they don't control. The public health interest in making safer nicotine products as accessible and affordable as possible is in tension with the patent system's grant of monopoly rights to the companies that developed the products. The tension is structural and, at present, almost entirely unaddressed by the regulatory framework.

The competitive dynamics of the nicotine patent landscape are complex and evolving. The major cigarette companies—PMI, BAT, JTI, Imperial Brands—are racing to build patent portfolios that cover the reduced-risk categories they are betting on. PMI's portfolio is strongest in heated tobacco (IQOS) and nicotine pouches (ZYN). BAT's portfolio is strongest in vaping (Vuse) and has significant holdings in pouches (Velo) and heated tobacco (glo). The independent vaping companies that drove the early innovation in the category—Juul, NJOY (before its acquisition by Altria), and the hundreds of smaller manufacturers—have historically been less aggressive in patenting, relying on trade secrets, first-mover advantages, and the fragmentation of the market to maintain their positions. That era is ending. As the regulatory environment consolidates around the major companies—the PMTA process, with its million-dollar-per-product cost, effectively excludes the independents—the patent landscape is becoming the primary arena of competition. The companies that own the patents will own the market that the regulatory system is creating.

The potential for patent-based market concentration is particularly acute in nicotine pouches, where Swedish Match (now PMI) holds foundational patents on the manufacturing process that produces the premium pouch experience. ZYN's market dominance—approximately 70% of the US pouch market—is protected not just by brand loyalty and distribution relationships, but by a patent portfolio that makes it difficult for competitors to produce a pouch with equivalent sensory characteristics without infringing. The patents cover what seems like basic technology: the nonwoven fabric that encases the nicotine powder, the specific blend of cellulose and other fillers that provides the right mouthfeel and nicotine release profile, the manufacturing process that produces a consistent, stable product. These are not exotic technologies. They are the result of decades of iterative improvement by Swedish Match's engineers, protected by patents that block competitors from following the same path. The public health implication is that the nicotine pouch market—the fastest-growing reduced-risk category—is likely to remain concentrated in the hands of a few patent-holding companies, with corresponding implications for price, access, and innovation.

The patent system is not going to be reformed for the sake of nicotine policy—and it probably shouldn't be. But the interaction between patent law and public health deserves more attention than it has received. The FDA's regulatory framework for nicotine products does not consider patent ownership or market concentration as factors in its public health determinations. The PMTA process evaluates whether a product is 'appropriate for the protection of public health' based on its individual characteristics—not on whether the market for that product is competitive or concentrated, affordable or prohibitively expensive, accessible to the smokers who need it or restricted to those who can pay. A more holistic approach would consider the market structure that the regulatory framework is creating—including the role of patents in shaping that structure—and would incorporate competition and access considerations into the public health calculus. The nicotine industry's transformation is being shaped by patents as much as by regulations. Ignoring the patent dimension is ignoring a primary driver of the market outcomes that public health depends on.

Shareable insight: The future of the nicotine industry is being decided not just in FDA hearings and public health conferences, but in patent offices and courtrooms. The companies that control the intellectual property for reduced-risk products—the patents on heating technology, nicotine formulations, pouch manufacturing—will control the market that the regulatory system is creating. The public health interest in making safer products accessible and affordable is in tension with the patent system's grant of monopoly rights. The tension is structural, growing, and almost entirely unaddressed.